PGT-A is an optional IVF test that checks a few cells from an embryo for chromosome count. Because it analyzes only a small sample, errors can occur in up to 25% of cases. Results may also be affected by mosaicism — a mix of normal and abnormal cells.

Clinically Unconvincing Results

PGT-A does not lead to better pregnancy or birth rates when all patients are included from the start of treatment.

Technical Errors

Inaccurate readings may occur due to mosaicism or DNA testing errors—these can affect up to 25% of results.

Unnecessary Discarding of Embryos

Embryos labeled “unsuitable” (e.g. mosaic) have resulted in healthy babies—meaning they may have been discarded unnecessarily.

Ethical and Financial Issues

The test is costly, emotionally exhausting, and often presented as “essential” despite limited evidence of benefit.

Key Takeaways

• PGT-A may not improve outcomes for many patients.
• Small sampling can lead to significant misinterpretation.
• Many embryos labeled “abnormal” may still result in live births.
• The financial and emotional toll may outweigh potential benefits.